JP2015516980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516980A5 JP2015516980A5 JP2015507531A JP2015507531A JP2015516980A5 JP 2015516980 A5 JP2015516980 A5 JP 2015516980A5 JP 2015507531 A JP2015507531 A JP 2015507531A JP 2015507531 A JP2015507531 A JP 2015507531A JP 2015516980 A5 JP2015516980 A5 JP 2015516980A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- bendamustine
- pharmaceutical composition
- seq
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12165660 | 2012-04-26 | ||
| EP12165660.7 | 2012-04-26 | ||
| EP12168397.3 | 2012-05-16 | ||
| EP12168397 | 2012-05-16 | ||
| PCT/EP2013/058617 WO2013160396A1 (en) | 2012-04-26 | 2013-04-25 | Combination of cd37 antibodies with bendamustine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516980A JP2015516980A (ja) | 2015-06-18 |
| JP2015516980A5 true JP2015516980A5 (enExample) | 2016-07-07 |
Family
ID=48227255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507531A Pending JP2015516980A (ja) | 2012-04-26 | 2013-04-25 | Ｃｄ３７抗体とベンダムスチンとの併用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20130287797A1 (enExample) |
| EP (1) | EP2841099A1 (enExample) |
| JP (1) | JP2015516980A (enExample) |
| WO (1) | WO2013160396A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| US8992915B2 (en) | 2012-05-16 | 2015-03-31 | Boehringer Ingelheim International Gmbh | Combination of CD37 antibodies with ICE |
| JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体の更なる薬剤との併用 |
| RS64576B1 (sr) * | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| KR20250175330A (ko) * | 2023-04-19 | 2025-12-16 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 다른 약제의 조합 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| ES2274823T3 (es) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica. |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| US7374762B2 (en) | 2003-05-14 | 2008-05-20 | Immunogen, Inc. | Drug conjugate composition |
| EP2295080A3 (en) * | 2005-07-25 | 2011-06-22 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| PT2132228E (pt) * | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体の更なる薬剤との併用 |
-
2013
- 2013-04-25 WO PCT/EP2013/058617 patent/WO2013160396A1/en not_active Ceased
- 2013-04-25 EP EP13719507.9A patent/EP2841099A1/en not_active Withdrawn
- 2013-04-25 US US13/870,487 patent/US20130287797A1/en not_active Abandoned
- 2013-04-25 JP JP2015507531A patent/JP2015516980A/ja active Pending
-
2015
- 2015-05-04 US US14/703,287 patent/US20150231242A1/en not_active Abandoned